Valneva (NASDAQ:VALN) Sees Strong Trading Volume

Shares of Valneva SE (NASDAQ:VALN) saw unusually-high trading volume on Friday . Approximately 4,092 shares were traded during mid-day trading, a decline of 61% from the previous session’s volume of 10,386 shares.The stock last traded at $7.37 and had previously closed at $7.35.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $26.00 price objective on shares of Valneva in a research note on Monday, June 24th. Guggenheim dropped their price objective on Valneva from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, March 22nd.

Valneva Price Performance

The company has a 50 day simple moving average of $7.87 and a 200-day simple moving average of $8.11. The stock has a market cap of $527.16 million, a price-to-earnings ratio of -18.34 and a beta of 2.20. The company has a current ratio of 2.64, a quick ratio of 2.22 and a debt-to-equity ratio of 0.84.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.12. The firm had revenue of $35.56 million for the quarter, compared to the consensus estimate of $95.80 million. Valneva had a negative return on equity of 14.56% and a negative net margin of 15.88%. Research analysts expect that Valneva SE will post -0.56 EPS for the current year.

Institutional Trading of Valneva

An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. lifted its stake in Valneva SE (NASDAQ:VALN) by 2.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 354,361 shares of the company’s stock after acquiring an additional 9,361 shares during the quarter. General American Investors Co. Inc. owned approximately 0.51% of Valneva worth $2,831,000 as of its most recent SEC filing. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.